OMB No. 0925-0001 and 0925-0002 (Rev. 12/2020 Approved Through 02/28/2023)

CV

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person**.**

**NAME**: Dr. Otuonye Ngozi Mirabel

eRA COMMONS USER NAME (credential, e.g., agency login):**Chidinma 12 ORCID iD** 0000-0001-5837-3967

**POSITION TITLE:** Deputy Director Medical Laboratory Services/Senior Lecturer. DOB-July, 22 1963

**EDUCATION/TRAINING** (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

| **INSTITUTION AND LOCATION** | DEGREE  (if applicable) | Start Date  MM/YYYY | Completion Date  MM/YYYY | FIELD OF STUDY | |
| --- | --- | --- | --- | --- | --- |
| 1. University of Benin Edo State Nigeria | PhD | August 2013 | September 2019 | Medical Microbiology |
| 1. University of Benin   Edo State Nigeria | MPhil | April 2009 | September 2010 | Animal Pathological Microbiology |
| 1. Edo State University   Ekpoma Edo State Nigeria | MSc | March 1993 | August 1995 | Medical Microbiology |
|  |  |  |  |  | |
| 1. . Sch. of Med. Lab. Science, LUTH, Idi Araba, Lagos, Nigeria | FIMLCN | January 1991 | December, 1992 | Microbiology | |
| 1. Sch. of Med. Lab. Science, UCTH, Calabar, Nigeria | AMLSCN | September 1984 | December  1988 | Haematology and Blood Transfusion Science | |
| 1. Microbiology Department, National Medical Laboratory Winnipeg Canada | Fellowship | February, 2016 | June 2017 | PCR, Gel, HLA Precipitation, HLA Sanger Sequencing  and typing | |
| 1. Grand Medical Foundation Pune India | Fellowship | March 2021 | May 2021 | HLA Typing and Cross Matching by Flow-cytometer | |
| 1. HLA Lab, Haematology Dept. OAUTH Ile-Ife, Osun State Nigeria | Fellowship | October 2021 | December, 2021 | Genomic Paternity Dispute using (DNA, PCR, HLA-ABDR-C, HLA- DP Typing by SSPCR Method | |

**Contribution to science**

**A. *My earlier project focused on the “Role of Human Leukocyte Antigen-C class 1 in HIV-1 Transmission among Serodiscordant Couples in Nigeria” This project recruited a total of 272 serodiscordant couples which received Couples HIV Voluntary Counselling and Testing. Laboratory tests on Microbial infections were done for couples who complained of PID and others. Result from the study showed that HLA alleles C\*070201 (OR = 4.19, P<0.05) and C\*0804 (OR = 3, P<0.045) were found to be independently associated with HIV-1 susceptibility in the cohort of serodiscordant couples. HLA-C\*0802 (OR=0.5. P<0.005) and C\*0304 (OR=0.34. P<0.002) were significantly associated with HIV-1 resistance to HIV-1 infection among the cohort. Articles published from this work include****:*

**1. Otuonye** NM, Ma Luo, EnabuleleOI, Ayorinde JB, Odunukwe NN *et al*. Human Leukocyte Antigen-C and Haplotypes: Associations with Resistance and Susceptibility to HIV-1 Infection among Serodiscordant Couples in Nigeria. EC Microbiology 2022; 18.3 24-36

**2. Otuonye** NM, Ma Luo, EnabuleleOI,Odunukwe NN *et al*.HLA-C Class I same Allele-Sharing Associated with high plasma viral load (HIV-1 RNA) and HIV-1 Transmission among Heterosexual Serodiscordant Couples in Nigeria. Accepted for publication by Journal of Genetic Syndrome and Gene Therapy. ID 101574143-2022

**3. Otuonye NM,** Luo Ma, Chris Chinweokwu Aniedobe MN,Okoye RN, Odunukwe NN*et al*. Plasma Viral Load in Microbial Infection and Antimicrobial Resistance among Heterosexual Serodiscordant Couples in Nigeria. Accepted for publication by Fortune Journals of Public Health No. FJHS5306-0001. 2022

**4. Otuonye NM**, Enabulele OI, Luo M, Odunukwe NN, Thomas B, Emele F *et al*. Human Leukocyte Antigen-C Class I Population -Based Ancestry of Genetic Ethnic Diversity in Nigeria. Int. Journal of Innovative and Advanced Studies 2019; 6:7. 53-56

**B. *We designed and participated on a 5 –Day Training workshop on SAR-CoV2 Partial Genome Sequencing: Building and Experience Capacity for COVID-19 Diagnosis in Nigeria. I presented Epidemiology of SARS-CoV-2 and Control Measures. I also won a grant on SARS CoV-2 Project. Articles published on SARS COV2 includes*:**

**1.Otuonye NM**, Olumade TJ, Ojetunde MM, Holdbrooke SA, Ayoola JB1, Itse Yusuf Nyam Iwalokun B Onwuamah C , Uwandu M *et al* . Clinical and Demographic Characteristics of COVID-19 Patients in Lagos, Nigeria: A Descriptive Study. Journal of the National Medical Association. <https://doi.org/10.1016/j.jnma.2020.11.011>

**2.** Chika Onwuamah, Okwuraiwe Azuka**, Ngozi Otuonye**, Tunde Salako *et al.* Two West African research institutes collaborate on whole-genome sequencing of SARS-CoV-2: Best-practice for the evolution of South-South partnerships. The Lancet Global Health 2021; 9 (11) E1499-E1500

**3. Otuonye NM.** Oduukwe NN, Ojetunde MM, Orok AB, Ayoola JB, Gab –Okafor C, Salako BL *et al*. Haemoglobin (Hb) Genotype Profile in COVID-19 Disease Susceptibility and Severity in Lagos State Nigeria Infectious Diseases Reviews, 2022; Volume 1, ID 613 DOI: 10.55085/idr.2022.613

**4.** Oduukwe NN, **Otuonye NM.** Ojetunde MM, Orok AB, B, Ezechi O2, Abimbola B, Salako BL *et al*.

ABO Blood Group Profile Frequencies and Relationship in COVID-19 Disease Susceptibility and Severity in Lagos, Nigeria Biomedical Journal of Scientific & Technical Research 41(4)-2022; BJSTR. MS.ID.006642.

**5**. Onwuamah CK, Iwalokun BA, Ahmed RA, Okwuraiwe AP, **Otuonye MN,** Mba N, Audu RA, Ezechi OC, Abayomi A, Adetifa I, Salako BL *et al.* Tracking SARS-CoV-2 variants from July 2021 to Jan 2022 in metropolitan Lagos, the epicentre of the COVID-19 pandemic in Nigeria. Accepted by ICMJE March, 2022.

**6**. Emelda Chukwu E, Nkiruka Odunukwe**,** Babatunde Salako, **Ngozi Otunoye** *et al* (2021). Determinants of Antimicrobial Use for COVID- 19 Related Symptoms among Nigerians. West Afr. J Med. Mar 22; 38(3):213-221.

**C. *I have also collaboration with other researchers to document findings on HIV/AIDS among women with vaginal discharge in Lagos and other states in Nigeria. Articles published from this work include:***

1. Ojetunde MM, Oyejobi G. Olaniyan S, Olumade T, **Otuonye NM** *et al*. Serologic Evidence of Exposure to Human Immunodeficiency Virus Type 1 and Dengue Virus among Diagnostic Laboratory Attendees in Lagos State, Nigeria. Scientia Africana 2022; 20(3):21-30. DOI: [10.4314/sa.v20i3.3](http://dx.doi.org/10.4314/sa.v20i3.3)
2. **Otuonye NM**, Onwuatuelo RT, Onwuamah CK, Okwuzu JO, Otuonye EI. (2012). Sexual Violence and HIV/AIDs in Girls and Young Women in South Western Nigeria. *NJCBR*. **6**: 47- 52.
3. **Otuonye NM**, Enabulele OI, Aluyi HSA and Onwuamah CK (2011). Sexually Transmitted Infections and HIV in Female Commercial Sex Workers in Lagos Nigeria. *NJCBR*. 5:1-6.
4. Emele EF, Agbonlahor DE, **Okoroma NM,** and Fadahunsi AA (2004). Comparative study on Vaginal Candidiasis in two dissimilar regions of Nigeria Sokoto and Epkoma. *Journal of Applied and Basic Sci.* **2.** 29-33.
5. Anorlu AI, Odunukwe NN. **Otuonye NM,** *et al* (2004)**.**Prevalence of HIV among women with vaginal discharge in a Gynaecologic clinic in Lagos. *JMNA* **96**.3: 367-371. =
6. **Otuonye NM,** Odunukwe NN, Smith SI, Chigbo RC, Idigbe EO *et al* (2004).Aetiological Agents of Vaginitis in Nigerian Women. *Br. J Biomed Sci* **61**. 4:171-178.
7. **Otuonye NM,** Olukoya DK, Odunukwe NN, Bamidele M *et al* (2002).HIV Association with Conventional Sexual Transmitted Diseases in Lagos, Nigeria. *West African Journal of M*edicine **21**: 153-156.

**D.** ***I was involved with randomized phase III clinical trial of Savvy from 2004 to 2007.In this role investigated bacteria, viruses, fungi and parasites causing STIs and HIV/AIDS in commercial sex workers (CSWs). The study explored the potential of SAVVY – a candidate vaginal microbicide gel - in prevention of HIV infection and STIs. This project was conducted in collaboration with Family Health International (FHI) North Carolina, USA. I was able to learn about research ethics and was exposed me to interpersonal skills communications. After the above study, I was able to implement and report selected studies;***

.

1. **Otuonye NM**, Onwuatuelo IR, Okwuzu JO, Onwuamah CK, Musa AZ, , Akintude GB, Fowora MA *et al.* Adolescents’ Perception of HIV Vaccine Trial in Nigeria. *NJCBR 2013*. 42-46.
2. **Otuonye NM**, Onwuatuelo RT, Onwuamah CK *et al*.. Vaginal Products and Hygiene Practices: Implications for Microbicides acceptability among Nigerian Women. *NJCBR 2012*. **6**: 47-53.
3. **Otuonye NM,** Odunukwe NN, Onwuatuelo FI, Adeneye AK, Idigbe EO *et al* (2006). Knowledge, Perception and Acceptability of Microbicides amongst Health Care givers in Lagos, Nigeria. *Br. J. Biomed Sci*. **63:**140-141.
4. Adeiga A, Oyekunle O, Oladele O, Smith S, Idika N, OyedejiKSO, Niemogha MT and **Otuonye MN**. Randomized Control Trial of Savvy and HIV in Nigeria (2006). NIMR 2006 ANNUAL REPORT[www.nimr.gov.ng/\_areports/2006.pdf](http://www.nimr.gov.ng/_areports/2006.pdf)

**E**. ***We Designed Training Curriculum for Ethics and Mentorship and obtained approval from National Health Ethics Committee, Ministry of Health Abuja, Nigeria to facilitate the following:***

1. A Four- day Training Programme on Human Subject Protection and Ethical Review of Research Protocol for Health Professionals, Lawyers, Clergies, Lecturers Community and Representatives. **Training Site 1:** Infectious Disease HospitalYaba, Lagos Nigeria 28thJuly 2011 to 1st August 2011,

**Training site 2:** Ambrose Ali University Ekpoma Edo State Nigeria 18-21 August, 2011

1. **Three- day NIMR/EDCTP Mentorship Training on Operationalizing Institute Review Board (IRB) and Research Monitoring for**: Doctors, Nurses, Biomedical Scientists, Pharmacists, Clergies, Lawyers and Community representatives selected from initial ethics training at Ambrose Alli University and Infectious Disease Hospital**.** These professionals were selected to constitute the Ethics Committee Members for their institutions. **Training site 3:** Nigerian Institute of Medical Research Yaba, Lagos, Nigeria. 14 -16August, 2012. **This project was sponsored by EDCTP**. I was able to implement the following reports below:
2. **Otuonye NM**, Nwaokorie FO, Suprumont D, **Otuonye EI**, Halidou T (2012).

Establishment of Health Research Ethics Committees and Capacity building of Human Resources and Infrastructure in Nigeria. *NIMR News* *vol* 1 (9) 13pp.

1. **Otuonye NM**, Nwaokorie FO, Suprumont D, Halidoub T, and Otuonye EI (2012). Human Subject Protection and Ethical Review of Research Protocol. **Name of Meeting**: International Union Against Sexually Transmitted Infections (IUSTI) World Congress. Melbourne, Victoria, Australia. 15th-17th October 2012 **Abstract Reference:** *Retrovirology,* 9 (Suppl 2) p233.

**Newspaper articles**

1. Follow WHO Standard Research Ethics Committee Told. National Mirror Wednesday Aug 2, 2012 pp22. **Otuonye NM**
2. Seminar on Medical Research Holds in Lagos. The Guardian Wednesday August 15th, 2012 pp6. **Otuonye NM**

**Published Books**

1. EO Idigbe, N. Idika, RA Audu, **NM Otuonye** and CK Onwuamah *et al* (2005): Directory of Stake Holders on HIV/AIDS in Nigeria. *NIMR and Federal Ministry of Health*.1st Edition: ISBN 978-38457-6-4: 345PP.

2. EO Idigbe, N. Idika, RA Audu, **NM Otuonye** *et al* (2003). Training Manual on Laboratory Tests for Diagnosis and Monitoring HIV infections in Nigeria in collaboration with NACA, APIN & NASCP, Ist Edition. ISBN 978-062-327-4.

3. EO Idigbe, N.Idika, RA Audu, **NM Otuonye** *et al* (2003*)*. Background Document for the Training Modules on Laboratory Tests and Monitoring of HIV infection in Nigeria. *NIMR, NACA, APIN & NASCP*, 1st Edition, ISBN 978-062-327-2.

**F. *Positions and Employment***

**1. Academic Appointment**

Adjunct Lecturer 1Immunology Dept., College of Medical Sciences, Nnamdi Azikiwe University Nnewi Campus Anambra State, Nigeria 2013-2019

**2. Appointment with the Nigerian Institute of Medical Research**

Deputy Director Laboratory Services/Laboratory Manager,

Central Research Laboratory, NIMR Yaba 2019 to now

Deputy Director Laboratory Services/Head of Unit, Clinical

Diagnostic Laboratory NIMR, Yaba 2016-2018

Chief Medical Laboratory Scientist/Laboratory Supervisor:

Clinical Diagnostic Laboratory NIMR, Yaba 2013-2015

Chief Medical Laboratory Scientist/Head of Unit:

Central Laboratory, NIMR Yaba 2009-2013

Chief Medical Laboratory Scientist: Clinical Science Division. NIMR

(Development of Clinical Science Division’s Laboratory) 2008-2009

Senior, Principal, Assistant Chief & Chief Medical Laboratory Scientist

Molecular Biology & Biotechnology Division, NIMR, Yaba 1996-2008

Medical Laboratory Scientist 1/Head of Unit**,**

Blood Bank, Irrua Specialist Teaching Hospital, Edo State, Nigeria 1993-1996

Medical Laboratory Scientist (NYSC):

Obafemi Awolowo University Teaching Hospital lle- Ife Osun State 1989-1990

**G. *Grant Awards***

1. 2022 Emory-Nigeria D43 program-Training Grant on Women and HIV Research
2. 2021 NIMR-Federal Government of Nigeria COVID-19 Research Support **(Grant code NMG-CIF-06-0024)**
3. 2020 Emory-Nigeria D43 program-Training Grant on Women and HIV Research
4. 2020-2021 Africa-India Mobility Three Months Travel Fellowship Award (AIMF) **(code AAS/AIMF19/043)**
5. 2018-2019 Pre -Doctoral Research Development Grant (PRDG) from Nigerian Institute of Medical Research Scientific Committee through its Graduate Initiative Programme (GIP). **(Code 1NIMR-PR-DG-0002-18-01/ 19-01)**
6. 2019-2020 Pre -Doctoral Research Development Grant (PRDG) from Nigerian Institute of Medical Research Scientific Committee through its Graduate Initiative Programme (GIP). **(Code 1NIMR-PR-DG-0002-19-01/ 20-01**
7. 2011-2012 Establishment of Health Research Ethics Committees and Capacity Building from European and Developing Clinical Trials Partnership {EDCTP}, The Hague, the Netherlands

**(Code CB.10.41302.027)**

1. 2012: HIV Research Trust Scholarship UK 2012 **(Code: HIVRT12-082)**
2. 2004-2006 Phase 111 Randomized Savvy (Microbicides) Clinical Trial

1. ***Selected Fellowship and travel grant Award***
2. **2021: African Indian Mobility Travel award** March-May 2021. This Fellowship award provided HLA Typing training at Ruby Hospital Grand Medical Hospital Pune India.
3. **2021: NIMR Fellowship Travel award October** -December 2021. This Fellowship award provided HLA Typing training at Haematology Dept, OAUTH, Ile –Ife Osun State Nigeria

1. **2019: First Humboldt Kolleg International Conference**. The grant covered registrations and feeding. **Location:** Nigerian Institute of Medical Research Yaba, Lagos Nigeria
2. **2018: African Academy of Science (AAS)**Evidence-Informed Policy Making Seminar –Water-Energy-Food-Health, Science. 627Jr Pretoria 0081. South Africa.
3. **2018: Global Health form for** Keystone Symposia; HIV and Co-Infections: Pathogenesis, Inflammation and Persistence. Whistler, British Columbia, Canada
4. **2016:** Prof Ma Lou of National Microbiology Laboratory, Winnipeg Manitoba Canada, for Annual Canadian Conference on HIV/AIDS Research.
5. **2015**:39th Asia-Pacific Histocompatibility and Immunogenetics Association Summer School. Bangkok. October, 2015
6. **2015:** Wellcome Trust Advanced Courses working with the Human Genome Sequence and Bioinformatics. Ayutaya Malawi.
7. **2013:** 7th Biannual European Developing Clinical Trial Partnership (EDCTP) Conference. **Darker Senegal.** October, 2013
8. **2012:** AIDS Vaccine Conference. The grant covered return flight ticket, accommodation, registrations and perdiem. Massachusetts
9. **2012:** International Union Against Sexually Transmitted Infections (IUSTI) World Congress. Melbourne, Victoria, Australia.
10. **2012: HIV Research Trust Fund United Kingdom. To Zambia Research HIV Research** Group for Couples HIV Voluntary Counseling and Testing Technical Assistance (TA) Meeting. Lusaka, Zambia**.**
11. **2011:** 6th European & Developing Countries Clinical Trials Partnership Forum (EDCTP). **Addis Ababa, Ethiopia.**
12. **2010:** National Health Institute USA on Reduction of Global Health Diseases on HIV/AIDS, TB, CVD and Malaria. Johannesburg October 2010
13. **2010:** Keystone symposium on HIV Vaccine. **Location**: Fairmont Banff Springs Alberta, Canada.
14. **2010:** Microbicides, 2010 Microbicide Conference. Pittsburgh, Pennsylvania USA
15. **2009: Global Health Travel for** Keystone symposium. **Location:** The grant covered return flight ticket, accommodation, registrations and perdiem. Colorado USA. March, 2009
16. **2009:** 5th Biennial EDCTP Forum. **Arusha Tanzania**.
17. **2009:** International Union Against Sexually Transmitted Infections (IUSTI) World Congress. **Cape Town, South Africa.**
18. **2008 11th**Annual Conference on Vaccine development and update**.** Baltimore USA
19. **2008:** AIDS Vaccine Conference.The grant covered return flight ticket, accommodation, registrations and perdiem.  **Cape Town, South Africa.**
20. **2008:** International Conference on AIDS and Sexually Transmitted Infections. **Senegal**
21. **2007:** 14th Conference on Retroviruses and Opportunistic Infections**.**  Los Angeles USA.

**I. Professional Memberships and Activities**

The Institute of Medical Laboratory Science Council Nigeria (FIMLS)-**Fellow** 1992-date

Nigeria Covid-19 Research Coalition (NCRC**) - Member** 2020-date

African Scientific Institute (ASI) - **Fellow** 2016-date

Institute of Biomedical Science, London (IBSL) -**Associate** 1996-date

Nigerian HIV Vaccine, Microbicide Advocacy Society (NHVMAS) - **Member** 2006-date

European Federation for Immunogenetics (EFI) -**Member**  2016-2018

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |